$6.69 Billion is the total value of Avoro Capital Advisors LLC's 36 reported holdings in Q4 2022. The portfolio turnover from Q3 2022 to Q4 2022 was 7.7% .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
UTHR | Sell | UNITED THERAPEUTICS CORP | $796,727,850 | +30.0% | 2,865,000 | -2.1% | 11.91% | +5.2% |
HZNP | Buy | HORIZON THERAPEUTICS PLC | $796,600,000 | +151.1% | 7,000,000 | +36.6% | 11.90% | +103.2% |
APLS | Buy | APELLIS PHARMACEUTICALS INC | $549,418,750 | -20.6% | 10,625,000 | +4.9% | 8.21% | -35.7% |
MDGL | Buy | MADRIGAL PHARMACEUTICALS INC | $481,815,000 | +383.0% | 1,660,000 | +8.1% | 7.20% | +290.7% |
ARGX | ARGENX SEsponsored adr | $479,430,201 | +7.3% | 1,265,555 | 0.0% | 7.16% | -13.2% | |
SRPT | SAREPTA THERAPEUTICS INC | $411,416,500 | +17.2% | 3,175,000 | 0.0% | 6.15% | -5.2% | |
ASND | Buy | ASCENDIS PHARMAsponsored adr | $378,603,000 | +28.6% | 3,100,000 | +8.8% | 5.66% | +4.1% |
BMRN | BIOMARIN PHARMACEUTICAL INC | $367,964,387 | +22.1% | 3,555,555 | 0.0% | 5.50% | -1.2% | |
FOLD | AMICUS THERAPEUTICS INC | $327,228,000 | +17.0% | 26,800,000 | 0.0% | 4.89% | -5.4% | |
ALNY | ALNYLAM PHARMACEUTICALS INC | $262,603,250 | +18.7% | 1,105,000 | 0.0% | 3.92% | -4.0% | |
MRTX | Buy | MIRATI THERAPEUTICS INC | $251,722,197 | -35.1% | 5,555,555 | +0.1% | 3.76% | -47.5% |
SGEN | Buy | SEAGEN INC | $242,241,350 | -5.1% | 1,885,000 | +1.1% | 3.62% | -23.2% |
XENE | XENON PHARMACEUTICALS INC | $193,207,000 | +9.2% | 4,900,000 | 0.0% | 2.89% | -11.7% | |
ISEE | Buy | IVERIC BIO INC | $144,517,500 | +36.5% | 6,750,000 | +14.4% | 2.16% | +10.5% |
KRYS | Buy | KRYSTAL BIOTECH INC | $111,700,200 | +25.7% | 1,410,000 | +10.6% | 1.67% | +1.6% |
BCRX | BIOCRYST PHARMACEUTICALS INC | $103,894,000 | -8.9% | 9,050,000 | 0.0% | 1.55% | -26.3% | |
KYMR | Buy | KYMERA THERAPEUTICS INC | $96,096,000 | +103.5% | 3,850,000 | +77.5% | 1.44% | +64.7% |
Buy | DICE THERAPEUTICS INC | $78,797,316 | +261.4% | 2,525,555 | +134.9% | 1.18% | +192.3% | |
SNDX | Buy | SYNDAX PHARMACEUTICALS INC | $67,442,500 | +26.3% | 2,650,000 | +19.3% | 1.01% | +2.1% |
CBAY | CYMABAY THERAPEUTICS INC | $64,581,000 | +79.1% | 10,300,000 | 0.0% | 0.96% | +44.9% | |
MNKD | MANNKIND CORP | $47,957,000 | +70.6% | 9,100,000 | 0.0% | 0.72% | +38.2% | |
Buy | NUVALENT INC | $46,324,428 | +127.1% | 1,555,555 | +48.2% | 0.69% | +83.6% | |
RNA | Buy | AVIDITY BIOSCIENCES INC | $45,489,500 | +92.1% | 2,050,000 | +41.4% | 0.68% | +55.6% |
IOVA | Sell | IOVANCE BIOTHERAPEUTICS INC | $44,857,800 | -48.1% | 7,020,000 | -22.2% | 0.67% | -58.0% |
MRSN | MERSANA THERAPEUTICS INC | $44,243,000 | -13.3% | 7,550,000 | 0.0% | 0.66% | -29.9% | |
KURA | Sell | KURA ONCOLOGY INC | $38,533,050 | -20.0% | 3,105,000 | -11.9% | 0.58% | -35.3% |
AADI BIOSCIENCES INC | $36,557,828 | -9.2% | 2,849,402 | 0.0% | 0.55% | -26.6% | ||
RARE | ULTRAGENYX PHARMACEUTICAL INC | $34,747,500 | +11.9% | 750,000 | 0.0% | 0.52% | -9.6% | |
GLUE | Buy | MONTE ROSA THERAPEUTICS INC | $32,913,250 | +19.8% | 4,325,000 | +28.6% | 0.49% | -3.1% |
PMVP | PMV PHARMACEUTICALS INC | $26,622,000 | -26.9% | 3,060,000 | 0.0% | 0.40% | -40.9% | |
Sell | AMYLYX PHARMACEUTICALS INC | $23,278,500 | +27.2% | 630,000 | -3.1% | 0.35% | +3.0% | |
DSGN | Buy | DESIGN THERAPEUTICS INC | $23,312,998 | -37.3% | 2,272,222 | +2.3% | 0.35% | -49.3% |
MARINUS PHARMACEUTICALS INC | $12,537,000 | -40.2% | 3,150,000 | 0.0% | 0.19% | -51.7% | ||
Buy | TANGO THERAPEUTICS INC | $11,890,000 | +111.9% | 1,640,000 | +5.8% | 0.18% | +71.2% | |
FENC | FENNEC PHARMACEUTICALS INC | $11,520,000 | +18.5% | 1,200,000 | 0.0% | 0.17% | -4.4% | |
IO BIOTECH INC | $4,728,531 | -15.1% | 2,055,883 | 0.0% | 0.07% | -31.1% | ||
BCAB | Exit | BIOATLA INC | $0 | – | -575,000 | -100.0% | -0.08% | – |
AMRN | Exit | AMARIN CORP PLCsponsored adr | $0 | – | -6,000,000 | -100.0% | -0.12% | – |
RLAY | Exit | RELAY THERAPEUTICS INC | $0 | – | -400,000 | -100.0% | -0.16% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-02-14
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
AMICUS THERAPEUTICS INC | 36 | Q3 2023 | 17.9% |
MIRATI THERAPEUTICS INC. | 35 | Q3 2023 | 17.2% |
BIOMARIN PHARMACEUTICAL INC | 31 | Q3 2023 | 8.0% |
SAREPTA THERAPUTICS INC | 28 | Q3 2023 | 14.8% |
ASCENDIS PHARMA | 28 | Q3 2023 | 9.1% |
ARGENX SE | 26 | Q3 2023 | 9.5% |
IOVANCE BIOTHERAPEUTICS INC | 26 | Q3 2023 | 9.1% |
FENNEC PHARMACEUTICALS INC | 25 | Q3 2023 | 0.4% |
MADRIGAL PHARMACEUTICALS INC | 22 | Q3 2023 | 7.2% |
XENON PHARMACEUTICALS INC | 22 | Q3 2023 | 3.3% |
View Avoro Capital Advisors LLC's complete holdings history.
Latest significant ownerships (13-D/G)
Filed | Shares | Percentage | |
---|---|---|---|
Adverum Biotechnologies, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
DICE Therapeutics, Inc. | February 14, 2023 | 2,525,555 | 5.3% |
IOVANCE BIOTHERAPEUTICS, INC. | February 14, 2023 | 7,020,000 | 4.4% |
IVERIC bio, Inc. | February 14, 2023 | 6,750,000 | 5.0% |
Kura Oncology, Inc. | February 14, 2023 | 3,105,000 | 4.5% |
Aadi Bioscience, Inc. | September 26, 2022 | 2,849,402 | 11.7% |
ARENA PHARMACEUTICALS INC | February 11, 2022 | 1,235,000 | 2.0% |
AVADEL PHARMACEUTICALS PLC | February 11, 2022 | 1,670,000 | 2.9% |
FENNEC PHARMACEUTICALS INC. | February 11, 2022 | 1,200,000 | 4.6% |
POINT Biopharma Global Inc.Sold out | February 11, 2022 | 0 | 0.0% |
View Avoro Capital Advisors LLC's complete significant-ownership history.
Latest filings
Type | Filed |
---|---|
SC 13G/A | 2024-04-23 |
13F-HR | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
View Avoro Capital Advisors LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.